Full factorial design assisted RP-UHPLC method development and study of stressed degradation of molnupiravir

Omar Faruk; Diponkor Kumar Shill; Dilshad Noor Lira; Abu Shara Shamsur Rouf; Uttom Kumar

doi:10.22456/2527-2616.134441

Authors

Omar Faruk Department of Pharmaceutical Technology, Faculty of Pharmacy - University of Dhaka
Diponkor Kumar Shill Department of Pharmacy, Faculty of Life & Earth Sciences - Jagannath University
Dilshad Noor Lira Department of Pharmaceutical Technology, Faculty of Pharmacy - University of Dhaka
Abu Shara Shamsur Rouf Department of Pharmaceutical Technology, Faculty of Pharmacy - University of Dhaka
Uttom Kumar Department of Pharmaceutical Technology, Faculty of Pharmacy - University of Dhaka https://orcid.org/0000-0001-9863-2564

DOI:

https://doi.org/10.22456/2527-2616.134441

Keywords:

Molnupiravir, RP-UHPLC, factorial, COVID-19, degradation

Abstract

To combat the SARS-CoV-2 addition of molnupiravir into the current therapeutic regimen has added new hopes. But currently, not so many analytical methods are available for analyzing molnupiravir. The current study aimed at developing a suitable and efficient RP-UHPLC method for molnupiravir capitalizing full factorial design. The optimized method involved the use of trifluoroacetic acid (0.1%): methanol at a ratio of 65:35 (%, v/v) with fortis diphenyl HPLC column (150 mm x 4.6 mm i.d. [internal diameter], 5 μm particle size). The method was found highly specific (purity index <1.5), linear (0.5-100 μg.mL^-1), accurate (~100%), precise, rugged, and robust (%RSD<2). A stress degradation study exhibited that 0.1N HCl at 100˚C (±1˚C) for 2 hours caused drug degradation crossing its limit (>10%), the drug is extremely susceptible to basic hydrolysis and 0.1N NaOH at room temperature for 1 min caused 65.43% degradation, exposure in 3% H₂O₂ at 100˚C (±1˚C) for 1 hours caused the drug degradation over 10%, and 5 days of exposure to short wavelength UV light caused 13.16% of drug degradation. The research work successfully developed an efficient and validated method for analyzing molnupiravir in the RP-UHPLC system. Moreover, the degradation study performed will aid in adding integral information related to the stability of the drug molecule.

Downloads

Download data is not yet available.

References

Worldometer [Internet]. Coronavirus cases, c2023 [cited 2023 June 27]. Available from: https://www.worldometers.info/coronavirus/#countrie s.

Nishiga M, Wang DW, Han Y, Lewis DB, Wu JC. COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. Nat Rev. 2020; 17:543-538.

Muniyappa R, Gubbi S. COVID-19 pandemic, coronaviruses, and diabetes mellitus. Am J Physiol - Endocrinol Metab. 2020; 318:736-741.

Kompaniyets L, Goodman AB, Belay B, Freedman DS, Sucosky MS, Lange SJ, et al. Body Mass Index and Risk for COVID-19–Related Hospitalization, Intensive Care Unit Admission, Invasive Mechanical Ventilation, and Death — United States, March– December 2020. MMWR Surveill Summ. 2021; 70(10):355-361.

Gordon CJ, Tchesnokov EP, Schinazi RF, Götte M. Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template. J Biol Chem. 2021;297(1),100770.

Ndwandwe D, Wiysonge CS. COVID-19 vaccines. Curr Opin Immunol. 2021; 71:111–6.

Mahase E. Covid-19: Molnupiravir reduces the risk of hospital admission or death by 50% in patients at risk, MSD reports. BMJ. 2021; 375.

Yoon JJ, Toots M, Lee S, Lee ME, Ludeke B, Luczo JM, et al. Orally efficacious broad-spectrum ribonucleoside analogue inhibitor of influenza and respiratory syncytial viruses. Antimicrob Agents Chemother. 2018; 62(8):e00766-00818.

Bernal AJ, da Silva MMG, Musungaie DB, Kovalchuk E, Gonzalez A, Reyes VD, et al. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. N Engl J Med. 2022; 386(6):509-520.

Painter WP, Holman W, Bush JA, Almazedi F, Malik H, Eraut NCJE, et al. Human safety, tolerability, and pharmacokinetics of molnupiravir, a novel broadspectrum oral antiviral agent with activity against SARS-CoV-2. Antimicrob Agents Chemother. 2021; 65(5).

Singh AK, Singh A, Singh R, Misra A. An updated practical guideline on the use of molnupiravir and comparison with agents having emergency use authorization for the treatment of COVID-19. Diabetes Metab Syndr Clin Res Rev. 2022; 16(2):102396.

Reçber T, Timur SS, Erdoğan Kablan S, Yalçın F, Karabulut TC, Neslihan Gürsoy R, et al. A stability indicating RP-HPLC method for determination of the COVID-19 drug molnupiravir applied using nanoformulations in permeability studies. J Pharm Biomed Anal. 2022; 214:114693.

Juran J, editor. Juran on quality by design: the new steps for planning quality into goods and services. New York: Free Press; 1992.

ICH Harmonized Tripartite Guidelines. Pharmaceutical development Q8(R2), 2009 [cited 2022 January]. Available from: https://database.ich.org/sites/default/files/Q8_R2_Gui deline.pdf.

U.S. Food and Drug Administration. Guidance for Industry: ICH Q8(R2) Pharmaceutical Development. November 2009 [cited 2022 January]. Available from: https://www.fda.gov/regulatory-information/searchfda-guidance-documents/q8r2-pharmaceuticaldevelopment.

U. S. Food and Drug Administration. Guidance for Industry: Q9 Quality Risk Management. Food and Drug Administration. May 2023 [cited May 2023]. Available from: https://www.fda.gov/media/167721/download.

Food and Drug Administration, HHS. International Conference on Harmonisation; guidance on Q10 Pharmaceutical Quality System; availability. Notice. Fed Regist. 2009; 74(66):15990-15991.

Tome T, Žigart N, Časar Z, Obreza A. Development and Optimization of Liquid Chromatography Analytical Methods by Using AQbD Principles: Overview and Recent Advances. Org Process Res Dev. 2019; 23:1784-1802.

Sultana S, Kumar U, Hossain MS, Lira DN, Rouf ASS. QbD approach for the development and validation of RP-UHPLC method for quantitation of vildagliptin. Dhaka Univ J Pharm Sci. 2017; 16(1):107-117.

Kovács B, Boda F, Fülöp I, Székely-Szentmiklósi I, Kelemen ÉK, Kovács-Deák B, et al. HPLC method development for fampridine using Analytical Quality by Design approach. Acta Pharm. 2020; 70(4):465- 482.

Das V, Bhairav B, Saudagar RB. Quality by design approaches to analytical method development. Res J Pharm Technol. 2017; 10:3188-3194.

Kumar L, Sreenivasa Reddy M, Managuli RS, Pai K. G. Full factorial design for optimization, development and validation of HPLC method to determine valsartan in nanoparticles. Saudi Pharm J. 2015; 23(5):549-555.

Sandhu PS, Beg S, Katare OP, Singh B. QbD-Driven Development and Validation of a HPLC Method for Estimation of Tamoxifen Citrate with Improved Performance. J Chromatogr Sci. 2016; 54(8):1377- 1384.

Kumar L, Reddy MS, Managuli RS, Pai G. Full factorial design for optimization, development and validation of HPLC method to determine valsartan in nanoparticles. Saud Pharm J. 2015; 23(5):549-555.

ICH Harmonized Tripartite Guidelines. Validation of analytical procedure: Text and methodology Q2(R1), 2005.

ICH Harmonized Tripartite Guidelines. Stability testing of new drug substances and products, Q1A (R2), 2003.

ICH Harmonized Tripartite Guidelines. Stability testing: Photostability testing of new drug substances and products, Q1B, 1996.

Saadati N, Abdullah MP, Zakaria Z, Sany SB, Rezayi M, Hassonizadeh H. Limit of detection and limit of quantification development procedures for organochlorine pesticides analysis in water and sediment matrices. Chem Cent J. 2013; 7(1), 63.

Shill DK, Kumar U, Al Hossain AM, Rahman MR, Rouf AS. Development and Optimization of RPUHPLC Method for Mesalamine Through QbD Approach. Dhaka Univ J Pharm Sci. 2022; 21(1):77- 84.